Tenofovir alafenamide (Vemlidy®) for the treatment of chronic hepatitis B infection

The National Health Care Institute carried out an assessment of the medicine tenofovir alafenamide (Vemlidy®). Based on the criteria of the Medicines Reimbursement System (GVS), tenofovir alafenamide fumarate (TAF) is interchangeable with tenofovir disoproxil fumarate (TDF), which is included on List 1B of the GVS.

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.